Team Elements Associated With Mortality in Intensive Care (TEAMIC)
Influence of Medical and Nursing Teams Composition on Patient Mortality in Intensive Care
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Antoine DUCLOS, MD, PhD
- Phone Number: +33 04 72 11 51 66
- Email: antoine.duclos@chu-lyon.fr
Study Contact Backup
- Name: Claude GUERIN, MD, PhD
- Phone Number: +33 04 26 10 94 18
- Email: claude.guerin@chu-lyon.fr
Study Locations
-
-
-
Lyon, France, 69317
- Service de Réanimation médicale, Hôpital de la Croix Rousse
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients who were admitted to 9 French intensive care units from January 1st 2011 to December 31st 2016
Exclusion Criteria:
- Patients admitted in pediatrics intensive care units and in specialized burns units
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Patient admitted to intensive care unit
All patients requiring intensive care unit stay
|
Assessment of the influence of team familiarity among the members of medical and nursing staffs on risk of patient death
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient mortality
Time Frame: At the time of intensive care unit discharge up to a maximum of 6 years since admission
|
Mortality with stratification on patients for whom a forego life-sustaining therapy decision was made
|
At the time of intensive care unit discharge up to a maximum of 6 years since admission
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 69HCL17_0031
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Death
-
NCT03070639CompletedSudden Infant Death Syndrome
-
NCT02376673CompletedSudden Infant Death Syndrome (SIDS)
-
NCT03213509CompletedPerinatal Death | Stillbirth | Neonatal Death
-
NCT03934242CompletedSudden Death in Children
-
NCT00570869CompletedPrevention of Sudden Death
-
NCT01321918TerminatedExtra-hospital Sudden Death
-
NCT01265277CompletedSudden Infant Death Syndrome
-
NCT00005567CompletedSudden Infant Death Syndrome
Clinical Trials on Deaths in intensive care unit
-
NCT02849756CompletedIntensive Care Unit Syndrome
-
NCT04914065CompletedQuality of Life | Weaning Failure | ICU Acquired Weakness
-
NCT03777150UnknownPostoperative Care | Intensive Care
-
NCT00184132Completed
-
NCT05153889RecruitingNon-ST Elevated Myocardial Infarction
-
NCT05474157TerminatedCovid19 | Sarcopenia | Intensive Care Unit Acquired Weakness